[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-001", "question": "A 45-year-old with severe ARDS on VV-ECMO develops suspected heparin-induced thrombocytopenia (4T score 6). Heparin is discontinued and argatroban initiated. The patient has significant hemolysis (plasma free hemoglobin 800 mg/dL). Which monitoring assay is most reliable for titrating argatroban in this setting?", "options": ["Activated partial thromboplastin time (aPTT)", "Anti-Xa chromogenic assay", "Anti-IIa (thrombin) chromogenic assay", "Activated clotting time (ACT)", "Dilute Russell viper venom time (dRVVT)"], "answer": "C", "answer_index": 2, "explanation": "Anti-IIa chromogenic assay directly measures thrombin inhibition by argatroban and is least affected by hemolysis, platelet count, or factor consumption seen in ECMO. aPTT is unreliable due to factor deficiency and hemolysis. Anti-Xa assays measure anti-Xa activity, not direct thrombin inhibitors. ACT is affected by platelets and fibrinogen. dRVVT is used for lupus anticoagulant detection.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The question asks for the most reliable monitoring assay for argatroban in a patient with severe hemolysis. Argatroban is a direct thrombin inhibitor.\n\nLet's analyze the options:\nA. Activated partial thromboplastin time (aPTT): While aPTT is commonly used to monitor argatroban, it is a global assay that can be significantly affected by hemolysis. Free hemoglobin released during hemolysis can interfere with the clotting process and lead to inaccurate aPTT results.\nB. Anti-Xa chromogenic assay: This assay measures the inhibition of Factor Xa. Argatroban is a direct thrombin inhibitor (inhibits Factor IIa), not a Factor Xa inhibitor. Therefore, this assay is inappropriate for monitoring argatroban.\nC. Anti-IIa (thrombin) chromogenic assay: This assay directly measures the inhibition of thrombin activity. Since argatroban's mechanism of action is to inhibit thrombin, this assay directly correlates with the drug's anticoagulant effect. Chromogenic assays are generally less susceptible to interference from hemolysis compared to global clotting assays.\nD. Activated clotting time (ACT): Similar to aPTT, ACT is a global assay that can be affected by various factors, including platelet count and hemolysis. It is not typically the most reliable assay for titrating direct thrombin inhibitors, especially in the presence of significant hemolysis.\nE. Dilute Russell viper venom time (dRVVT): This assay is primarily used for screening for lupus anticoagulants and is not a standard method for monitoring argatroban therapy.\n\nGiven the presence of significant hemolysis, which interferes with global clotting assays like aPTT and ACT, and that argatroban is a direct thrombin inhibitor, the anti-IIa chromogenic assay is the most reliable method for monitoring its efficacy in this setting.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-002", "question": "A 62-year-old with metastatic pancreatic adenocarcinoma on gemcitabine presents with acute kidney injury (creatinine 3.2 mg/dL), platelet count 45,000/µL, schistocytes, LDH 2200 IU/L, and haptoglobin <10 mg/dL. ADAMTS13 activity is 35%. What is the most appropriate initial management?", "options": ["Urgent plasma exchange", "Eculizumab therapy", "Discontinue gemcitabine and provide supportive care", "Rituximab 375 mg/m² weekly", "Caplacizumab 10 mg daily"], "answer": "C", "answer_index": 2, "explanation": "Gemcitabine-induced thrombotic microangiopathy is a drug-mediated toxicity, not complement-mediated or immune-mediated. ADAMTS13 is not severely deficient (<10%), excluding TTP. Plasma exchange is ineffective. Eculizumab and caplacizumab are reserved for complement-mediated aHUS. Rituximab is for TTP. The cornerstone of management is immediate discontinuation of gemcitabine.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with a clinical picture highly suggestive of a thrombotic microangiopathy (TMA). Key findings include thrombocytopenia (platelet count 45,000/µL), microangiopathic hemolytic anemia (MAHA) indicated by schistocytes on peripheral smear, elevated LDH, and low haptoglobin. Additionally, there is acute kidney injury (AKI). The ADAMTS13 activity is 35%.\n\nThe differential diagnosis for MAHA with thrombocytopenia and AKI includes Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS). Differentiation is often based on ADAMTS13 activity.\n-   TTP: Characterized by severe deficiency of ADAMTS13 activity (<10%), leading to accumulation of ultra-large von Willebrand factor (ULVWF) multimers, microthrombi formation, and microangiopathic hemolytic anemia. Acquired TTP is typically autoimmune, mediated by antibodies against ADAMTS13.\n-   HUS: While STEC-HUS usually has normal ADAMTS13 activity, atypical HUS (aHUS) is related to complement dysregulation and also typically has normal ADAMTS13 activity.\n\nIn this case, the ADAMTS13 activity is 35%. While not severely deficient (<10%), it is significantly reduced and below the normal range (typically >50-70%). Current guidelines suggest that in the presence of TMA (thrombocytopenia, MAHA, renal/neurological involvement) and ADAMTS13 activity <50%, TTP should be strongly considered and treated accordingly. Gemcitabine is a known drug that can induce TTP.\n\nLet's evaluate the options:\nA.  Urgent plasma exchange: Plasma exchange is the cornerstone of treatment for acquired TTP. It removes autoantibodies against ADAMTS13 and replenishes functional ADAMTS13 levels. Given the TMA symptoms and ADAMTS13 activity of 35%, plasma exchange is indicated.\nB.  Eculizumab therapy: Eculizumab is a complement inhibitor used for atypical HUS (aHUS). It is not the first-line treatment for TTP.\nC.  Discontinue gemcitabine and provide supportive care: Discontinuing the offending drug is important, especially since gemcitabine is known to cause TTP. However, with active TMA and significantly reduced ADAMTS13 activity, stopping the drug alone may not be sufficient to halt the microvascular damage. Aggressive treatment for TTP is usually warranted.\nD.  Rituximab 375 mg/m² weekly: Rituximab is an immunosuppressant often used as a second-line or adjunctive therapy for refractory or relapsed autoimmune TTP, targeting B cells that produce antibodies. It is not typically the initial therapy.\nE.  Caplacizumab 10 mg daily: Caplacizumab is an anti-VWF nanobody that inhibits VWF-platelet interaction. It is used for acquired TTP, usually in conjunction with plasma exchange and immunosuppression. It is an adjunct to plasma exchange rather than a standalone initial therapy that replaces it when ADAMTS13 is low.\n\nGiven the patient's critical findings of active TMA and a significantly reduced ADAMTS13 activity of 35%, urgent plasma exchange is the most appropriate initial management to address the presumed underlying cause of TTP, in conjunction with discontinuing gemcitabine.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-003", "question": "A 28-year-old presents 2 hours after ingesting barium carbonate with profuse vomiting, diarrhea, and profound muscle weakness. Serum potassium is 2.1 mEq/L with ST-segment depression on ECG. What is the primary mechanism of hypokalemia and most effective elimination strategy?", "options": ["GI losses; emergent hemodialysis", "Intracellular shift via K+ channel blockade; oral sodium sulfate", "Renal tubular wasting; potassium-sparing diuretics", "Beta-agonist effect; beta-blockade therapy", "Insulin-mediated shift; IV insulin with glucose"], "answer": "B", "answer_index": 1, "explanation": "Barium blocks voltage-gated potassium channels (Kv), preventing cellular efflux and causing intracellular K+ sequestration. Hemodialysis is ineffective due to barium's large volume of distribution (1.5 L/kg). Oral sodium sulfate precipitates residual Ba2+ as insoluble BaSO4 in the GI tract if administered within 24 hours, preventing further absorption. Massive IV potassium replacement is necessary but does not address elimination.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Barium carbonate ingestion can lead to toxicity due to the barium ion (Ba²⁺). Barium is a gastrointestinal irritant, causing symptoms such as vomiting and diarrhea, which lead to significant electrolyte losses, including potassium. However, barium also has direct toxic effects on cellular ion transport. Barium ions are known to block various potassium channels, including inwardly rectifying potassium channels and ATP-sensitive potassium channels. This blockade can impair the efflux of potassium from cells, leading to intracellular accumulation of potassium and thus extracellular hypokalemia. While GI losses contribute, the direct effect of barium on potassium channels is considered a primary mechanism contributing to severe hypokalemia in barium poisoning, which can cause muscle weakness and ECG abnormalities.\n\nThe most effective strategy to eliminate ingested barium and prevent further absorption involves binding it in the gastrointestinal tract to form insoluble barium sulfate. Oral administration of sodium sulfate achieves this by reacting with ingested barium carbonate to form barium sulfate, which is poorly absorbed and excreted.\n\nLet's evaluate the options:\nA. GI losses are a contributing factor, but emergent hemodialysis is a treatment for hyperkalemia, not hypokalemia.\nB. Intracellular shift via K+ channel blockade is a recognized mechanism of barium toxicity affecting potassium homeostasis, leading to hypokalemia. Oral sodium sulfate is the correct strategy to eliminate ingested barium by forming insoluble barium sulfate.\nC. Renal tubular wasting is not the primary mechanism of barium-induced hypokalemia. Potassium-sparing diuretics would increase serum potassium, which is contraindicated.\nD. Beta-agonist effects cause intracellular shifts of potassium. Barium is not a beta-agonist, and beta-blockade would be inappropriate.\nE. Insulin-mediated shifts cause potassium to move into cells, leading to hypokalemia. Barium does not directly stimulate insulin release. IV insulin with glucose is used to treat hyperkalemia, not hypokalemia.\n\nTherefore, option B best describes the primary mechanism and the most effective elimination strategy in this scenario.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-004", "question": "A 3-month-old infant presents with intractable seizures, hypotonia, and developmental regression. Brain MRI shows bilateral globus pallidus hyperintensity. Plasma creatine level is low. Which test provides the most specific diagnosis for guanidinoacetate methyltransferase (GAMT) deficiency?", "options": ["Plasma guanidinoacetate measurement", "Urine creatine:creatinine ratio", "Cerebrospinal fluid guanidinoacetate level", "GAMT gene sequencing", "Brain magnetic resonance spectroscopy"], "answer": "C", "answer_index": 2, "explanation": "CSF guanidinoacetate is the most sensitive and specific biomarker for GAMT deficiency due to accumulation behind the blood-brain barrier. Plasma GAA can be normal in mild cases. Urine ratio is supportive but nonspecific. GAMT sequencing may miss deep intronic variants or large deletions. MRS shows absent creatine peak but does not identify the specific enzyme defect.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The question asks for the most specific test to diagnose Guanidinoacetate Methyltransferase (GAMT) deficiency. Let's analyze the information provided and the options:\n\n*   Clinical presentation: 3-month-old infant with intractable seizures, hypotonia, and developmental regression.\n*   Brain MRI: Bilateral globus pallidus hyperintensity, suggestive of creatine deficiency syndromes.\n*   Plasma creatine level: Low, confirming a creatine deficiency syndrome.\n\nThere are three main creatine deficiency syndromes:\n1.  X-linked creatine transporter deficiency (SLC6A8).\n2.  Guanidinoacetate methyltransferase (GAMT) deficiency.\n3.  Arginine:glycine amidinotransferase (AGAT) deficiency.\n\nThe symptoms and MRI findings are common to all three. The low plasma creatine level confirms it's one of these. To specifically diagnose GAMT deficiency and differentiate it from the others, we need to assess guanidinoacetate (GAA) and creatine metabolism.\n\nLet's evaluate the options:\nA.  Plasma guanidinoacetate measurement: In GAMT deficiency, the enzyme responsible for converting guanidinoacetate to creatine is deficient. This leads to an accumulation of guanidinoacetate in plasma and cerebrospinal fluid (CSF), along with low creatine levels. Elevated plasma GAA is a highly specific biochemical marker for GAMT deficiency, distinguishing it from creatine transporter deficiency (which has normal GAA) and AGAT deficiency (which has low GAA).\nB.  Urine creatine:creatinine ratio: While altered, this ratio is not as specific for pinpointing GAMT deficiency as direct measurement of GAA.\nC.  Cerebrospinal fluid guanidinoacetate level: CSF GAA is also elevated in GAMT deficiency and is diagnostic. However, plasma measurement is typically less invasive and serves as the primary diagnostic tool before CSF analysis. Plasma GAA is generally considered sufficient to make the diagnosis.\nD.  GAMT gene sequencing: This test directly identifies mutations in the GAMT gene. Finding pathogenic mutations in this gene is the definitive molecular confirmation of GAMT deficiency. It provides the ultimate etiological specificity.\nE.  Brain magnetic resonance spectroscopy (MRS): MRS can show reduced creatine levels in the brain, which supports a creatine deficiency disorder, but it does not differentiate between the specific types of these disorders.\n\nComparison of A and D:\nOption A (Plasma guanidinoacetate measurement) provides a highly specific biochemical diagnosis. Elevated plasma GAA is the hallmark of GAMT deficiency.\nOption D (GAMT gene sequencing) provides a definitive genetic diagnosis. It confirms the underlying genetic cause of the disorder.\n\nIn the diagnosis of inherited metabolic disorders, genetic testing is often considered the gold standard for definitive confirmation and provides the most specific etiological diagnosis. While plasma GAA measurement is highly specific biochemically and essential for diagnosing the condition, gene sequencing confirms the specific genetic defect responsible for the enzyme deficiency. Therefore, it offers the most specific diagnosis of GAMT deficiency.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-005", "question": "A 58-year-old develops progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia over 18 months. CSF shows mild lymphocytic pleocytosis. Which antibody and pathological finding are most characteristic?", "options": ["Anti-Hu; neuronal nuclear inclusions", "Anti-NMDA receptor; perivascular lymphocytic cuffing", "Anti-IgLON5; tau deposition in brainstem and hypothalamus", "Anti-LGI1; faciobrachial dystonic seizures", "Anti-GAD65; cerebellar Purkinje cell loss"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease presents with sleep dysfunction (non-REM parasomnia, obstructive apnea) and bulbar symptoms, distinct from other autoimmune encephalitides. Unlike typical antibody-mediated diseases, it is characterized by tauopathy (4R-tau deposition) in the brainstem and hypothalamus on autopsy, correlating with poor response to immunotherapy. Anti-Hu is associated with small cell lung cancer and sensory neuropathy. Anti-LGI1 presents with faciobrachial dystonic seizures and hyponatremia.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with a constellation of symptoms: progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia, developing over 18 months, with CSF showing mild lymphocytic pleocytosis.\n\nLet's analyze each option:\nA. Anti-Hu; neuronal nuclear inclusions: Anti-Hu antibodies are associated with paraneoplastic syndromes, typically occurring with small cell lung cancer. While ataxia and bulbar symptoms can occur, prominent, progressive non-REM parasomnia and OSA are not characteristic primary features.\nB. Anti-NMDA receptor; perivascular lymphocytic cuffing: Anti-NMDA receptor encephalitis often presents with psychiatric features, seizures, and movement disorders, typically in younger individuals. While CSF pleocytosis is common, non-REM parasomnia and OSA are not typical hallmarks.\nC. Anti-IgLON5; tau deposition in brainstem and hypothalamus: Anti-IgLON5 disease is an autoimmune disorder that classically presents with sleep disturbances (including non-REM parasomnias and REM sleep behavior disorder), bulbar dysfunction (dysphagia, dysarthria), gait ataxia, and sometimes ophthalmoparesis. Pathologically, it is characterized by deposition of hyperphosphorylated tau (neurofibrillary tangles) in the brainstem and hypothalamus. This option aligns very well with the described clinical presentation.\nD. Anti-LGI1; faciobrachial dystonic seizures: Anti-LGI1 encephalitis is primarily known for limbic encephalitis and faciobrachial dystonic seizures (FBDS). While other neurological deficits can occur, the prominent non-REM parasomnia and OSA are less characteristic, and FBDS are a key feature that is not mentioned.\nE. Anti-GAD65; cerebellar Purkinje cell loss: Anti-GAD65 antibodies are associated with autoimmune cerebellar ataxia and stiff-person syndrome. While gait ataxia is present, the significant non-REM parasomnia and bulbar dysfunction are not the most characteristic features.\n\nConsidering the progressive non-REM parasomnia, bulbar dysfunction, and gait ataxia in an adult with inflammatory CSF, Anti-IgLON5 disease is the most fitting diagnosis. The proposed pathological finding of tau deposition in the brainstem and hypothalamus is also consistent with the proposed antibody and location of pathology causing the symptoms.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-006", "question": "During VV-ECMO for severe ARDS, the circuit suddenly shows extensive air with the patient becoming pulseless. What is the immediate management step?", "options": ["Place patient in left lateral decubitus and Trendelenburg position while continuing pump", "Clamp venous line, stop pump, aspirate from arterial port", "Increase ECMO flow to 6 L/min to clear air emboli", "Administer 100% oxygen and initiate CPR", "Convert circuit to VA-ECMO configuration"], "answer": "B", "answer_index": 1, "explanation": "In VV-ECMO, air embolism is venous. The immediate action is to stop the pump to halt further embolization, clamp the venous line to prevent additional air entry, and aspirate air from the arterial (outflow) line port. Durant's position is ineffective for venous emboli. Increasing pump flow worsens embolization. CPR is secondary to circuit management. Configuration change does not address the acute air emergency.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\nThe scenario describes a critical emergency: extensive air in the VV-ECMO circuit leading to patient pulselessness, strongly suggesting an air embolism. The immediate management must address the cause of the patient's deterioration.\n\nLet's analyze the options:\nA. Placing the patient in specific positions (left lateral decubitus and Trendelenburg) is a maneuver to manage air bubbles, but continuing the pump with air in the circuit is dangerous and would exacerbate the air embolism.\nB. Clamping the venous line prevents further air from entering the circuit. Stopping the pump prevents air from being pumped into the patient. Aspirating from the arterial port is a crucial step to remove trapped air from the circuit. These actions directly address the source and propagation of the air embolism.\nC. Increasing ECMO flow would likely force more air into the patient if air is already in the circuit, which is counterproductive and dangerous.\nD. Administering 100% oxygen and initiating CPR are vital for a pulseless patient. However, addressing the reversible cause of the pulselessness (air embolism) is the immediate priority to make resuscitation efforts effective.\nE. Converting the circuit to VA-ECMO configuration is a complex procedure not indicated for immediate management of air embolism and would take time, during which air could continue to enter the patient.\n\nThe immediate priority in managing an air embolism during ECMO is to stop further air from entering the patient's circulation and to remove air from the circuit. Option B outlines precisely these critical steps in a logical sequence: first prevent further ingress (clamp venous line), then stop propagation (stop pump), and then actively clear the circuit (aspirate from arterial port). While CPR is essential for the pulseless patient, addressing the reversible cause (air embolism) is the immediate critical management step.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-007", "question": "A 22-year-old with relapsed ALL receives axicabtagene ciloleucel. On day 12, he develops status epilepticus and CT shows cerebral edema, unresponsive to methylprednisolone 1 g/day for 3 days. What is the most appropriate next therapy for steroid-refractory ICANS?", "options": ["Increase methylprednisolone to 2 g/day", "Anakinra 100 mg intravenously", "Tocilizumab 8 mg/kg intravenously", "Cyclophosphamide 500 mg/m²", "Therapeutic plasma exchange"], "answer": "B", "answer_index": 1, "explanation": "Anakinra, an IL-1 receptor antagonist, is the preferred therapy for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). Tocilizumab targets IL-6 and is effective for cytokine release syndrome but has limited efficacy for ICANS. Escalating steroids beyond 1 g/day provides minimal additional benefit. Cyclophosphamide is not used for ICANS. Plasma exchange would eliminate the therapeutic CAR-T cells.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient is experiencing status epilepticus and cerebral edema on day 12 after receiving axicabtagene ciloleucel (a CAR T-cell therapy). This is highly suggestive of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). The problem states that these symptoms are unresponsive to high-dose methylprednisolone (1 g/day for 3 days), classifying this as steroid-refractory ICANS.\n\nWe need to assess the best next therapy for steroid-refractory ICANS.\n\nA. Increasing methylprednisolone: The patient has already received a high dose for 3 days without response. Further increasing the steroid dose alone is not typically the next step for steroid-refractory disease.\n\nB. Anakinra: Anakinra is an IL-1 receptor antagonist. While IL-1 can contribute to inflammation, IL-6 is considered a more central mediator in CAR T-cell toxicity syndromes. Anakinra is not a standard primary treatment for ICANS.\n\nC. Tocilizumab: Tocilizumab is an IL-6 receptor antagonist. Interleukin-6 (IL-6) plays a critical role in both cytokine release syndrome (CRS) and ICANS associated with CAR T-cell therapy. Guidelines often recommend tocilizumab for severe CRS and for ICANS, especially when it's refractory to steroids. It is frequently used as the next step after or in combination with steroids if symptoms persist or worsen.\n\nD. Cyclophosphamide: Cyclophosphamide is an immunosuppressant chemotherapy agent and is not indicated for the management of CAR T-cell-related neurotoxicity.\n\nE. Therapeutic plasma exchange (TPE): TPE is an option for severe, refractory CRS or ICANS, particularly if there is rapid deterioration or if other treatments fail. However, tocilizumab is usually a more immediate consideration for steroid-refractory ICANS due to its targeted action on IL-6. TPE might be considered as a rescue therapy if tocilizumab also fails or is contraindicated.\n\nGiven the steroid-refractory nature of the ICANS, tocilizumab is the most appropriate next therapy to attempt to control the cytokine storm contributing to the neurotoxicity.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "NOT FOR CLINICAL USE.\n\nThe scenario describes a patient in refractory shock and bradycardia following a massive ingestion of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. This therapy is a cornerstone for managing severe calcium channel blocker (CCB) and beta-blocker (BB) toxicity, as insulin has positive inotropic and chronotropic effects independent of its glucose-lowering action.\n\nLet's evaluate the options:\nA. 0.5-1 unit/kg/hr; check glucose every 2 hours: While this is a common starting dose for insulin therapy, for severe poisoning leading to refractory shock, higher doses are often required. Checking glucose every 2 hours is acceptable but hourly checks are preferred for higher doses.\n\nB. 1-10 units/kg/hr; check glucose every hour: This dosing range is broadly cited for HIET in severe CCB/BB toxicity, often starting with a bolus of 1 unit/kg followed by an infusion of 0.5-10 units/kg/hr. For refractory shock and a massive overdose (10g verapamil), higher doses within this range are frequently necessary. Checking glucose every hour is crucial to monitor for and promptly treat potential hypoglycemia, which is a significant risk when administering high doses of insulin.\n\nC. 0.1-0.5 units/kg/hr; check potassium every 4 hours: This dosing range is too low for treating severe cardiotoxicity from verapamil overdose. Furthermore, checking potassium only every 4 hours is insufficient, as insulin drives potassium into cells, potentially leading to clinically significant hypokalemia requiring frequent monitoring (every 1-4 hours).\n\nD. 5-20 units/kg/hr; check lactate every 2 hours: While 5-10 units/kg/hr is a reasonable infusion rate for severe toxicity, the upper end of 20 units/kg/hr might be extremely high for an initial infusion without a bolus, though possible for unremitting cases. Lactate is a marker of tissue perfusion but glucose and potassium are the primary monitored parameters for managing HIET itself.\n\nE. 2-5 units/kg/hr; check pH every 4 hours: This dosing range is plausible, but the primary monitoring for HIET should focus on glucose and potassium, not pH, and the frequency of 4 hours is too long for any critical parameter.\n\nConsidering the severity of the presentation (refractory shock) and the massive overdose, aggressive insulin dosing is indicated. Option B provides the most appropriate and commonly recommended range for both insulin infusion and glucose monitoring frequency in this critical scenario.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-009", "question": "A 6-month-old male infant presents with severe eczema, petechiae, recurrent otitis media, and platelet count of 30,000/µL with small platelet volume. What is the most sensitive diagnostic test for Wiskott-Aldrich syndrome?", "options": ["WASP gene sequencing", "Platelet-associated antibody testing", "Lymphocyte subset enumeration", "WASP protein expression by flow cytometry", "Serum IgE and IgA levels"], "answer": "D", "answer_index": 3, "explanation": "Flow cytometry for WASP protein expression in lymphocytes is more sensitive than standard gene sequencing, which may miss large deletions, splice site mutations, or deep intronic variants. Absent or reduced WASP protein expression confirms the diagnosis. Platelet antibodies are negative. Lymphocyte subsets are variable. IgE is elevated and IgA is low but these are nonspecific.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a classic triad suggestive of Wiskott-Aldrich Syndrome (WAS): eczema, recurrent infections (otitis media), and thrombocytopenia (petechiae, low platelet count with small platelets). WAS is an X-linked recessive disorder caused by mutations in the WAS gene, which encodes the Wiskott-Aldrich syndrome protein (WASP). WASP is crucial for the development and function of immune cells (T cells, B cells, NK cells) and platelets.\n\nLet's analyze the options for the most sensitive diagnostic test:\nA. WASP gene sequencing: This test identifies mutations in the WAS gene. It is definitive for confirming the genetic basis of WAS and is essential for genetic counseling. However, the question asks for the *most sensitive* diagnostic test, which often refers to detecting the functional defect or the disease state itself.\nB. Platelet-associated antibody testing: This test is used to diagnose immune thrombocytopenic purpura (ITP). While WAS patients have thrombocytopenia, it is usually due to impaired platelet production and survival related to WASP dysfunction, not primarily antibody-mediated destruction like in ITP. Therefore, this test is not sensitive or specific for WAS.\nC. Lymphocyte subset enumeration: While immune deficiency is a hallmark of WAS, lymphocyte subset analysis can show various abnormalities but is not specific to WAS. It helps characterize the immunodeficiency but is not the most sensitive test for diagnosing WAS itself.\nD. WASP protein expression by flow cytometry: WAS is characterized by the absence or severe deficiency of WASP protein in lymphocytes, platelets, and myeloid cells. Flow cytometry is a highly sensitive and specific method to directly detect the presence or absence of WASP protein in these cell populations. In classic WAS, there is a near-complete absence of WASP protein, which can be readily identified by flow cytometry. This is widely considered the gold standard and most sensitive diagnostic test for classic WAS.\nE. Serum IgE and IgA levels: Elevated IgE levels are common in WAS, but this finding is not specific and can be seen in other conditions like allergic diseases or other immunodeficiencies. It is a supportive finding rather than a primary diagnostic test.\n\nComparing options A and D, while gene sequencing confirms the genetic cause, flow cytometry for WASP protein expression directly demonstrates the functional defect underlying the clinical manifestations of WAS, making it the most sensitive and direct diagnostic test for the disease state in classic WAS.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-010", "question": "A 28-year-old develops progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over 3 years. EEG shows generalized spike-wave discharges. Which test is most specific for diagnosing Kufs disease (adult neuronal ceroid lipofuscinosis)?", "options": ["Epilepsy gene panel (SCN1A, GABRG2)", "Brain biopsy with periodic acid-Schiff staining", "Skin biopsy with electron microscopy", "CSF 14-3-3 protein immunoassay", "Serum anti-GAD65 antibody titer"], "answer": "C", "answer_index": 2, "explanation": "Electron microscopy of skin biopsy showing fingerprint profiles or granular osmiophilic deposits is the most specific diagnostic test for neuronal ceroid lipofuscinosis. Genetic testing (CLN6, CLN8, CTSF) is confirmatory but may be negative in variant forms. Brain biopsy is invasive and unnecessary. CSF 14-3-3 protein is elevated in Creutzfeldt-Jakob disease. Anti-GAD65 antibodies are associated with autoimmune epilepsy, not NCL.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The question describes a patient with progressive neurological symptoms including myoclonus epilepsy, cerebellar ataxia, and visual loss, with EEG showing generalized spike-wave discharges. This presentation in an adult is highly suggestive of Kufs disease, which is an adult-onset form of neuronal ceroid lipofuscinosis (NCL). NCLs are lysosomal storage diseases characterized by the accumulation of autofluorescent ceroid-lipofuscin material within cells, particularly neurons.\n\nLet's evaluate the given options:\n\nA. Epilepsy gene panel (SCN1A, GABRG2): Mutations in SCN1A and GABRG2 are associated with certain types of epilepsy, but not typically with Kufs disease. Genes implicated in Kufs disease are different (e.g., CLN3, CLN5, CLN6, CLN7, CLN8, GRN, CTSD, etc.). Therefore, this option is unlikely to be the most specific for Kufs disease.\n\nB. Brain biopsy with periodic acid-Schiff (PAS) staining: While a brain biopsy can be diagnostic, it is invasive. PAS staining can demonstrate the presence of some lysosomal material, but it is not specific enough to definitively diagnose NCLs over other lysosomal storage disorders. Electron microscopy is required to characterize the specific ultrastructural abnormalities seen in NCLs.\n\nC. Skin biopsy with electron microscopy: This is a highly specific diagnostic test for NCLs. Electron microscopy of fibroblasts obtained from a skin biopsy can reveal the pathognomonic ultrastructural features of the storage material, such as curvilinear profiles, fingerprint profiles, or granular osmiophilic deposits. These findings are characteristic of NCLs, including Kufs disease.\n\nD. CSF 14-3-3 protein immunoassay: This test is primarily used to support the diagnosis of Creutzfeldt-Jakob disease (CJD), a rapidly progressive prion disease, and is not specific for NCLs.\n\nE. Serum anti-GAD65 antibody titer: Elevated anti-GAD65 antibodies are associated with autoimmune disorders like limbic encephalitis and stiff-person syndrome, which can cause epilepsy but do not typically present with the specific triad of progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over years as seen in Kufs disease.\n\nAmong the given options, electron microscopy of a skin biopsy is the most specific method for visualizing the characteristic ultrastructural pathology of NCLs, making it a gold standard in diagnosis when genetic confirmation is not yet available or when confirming findings.\n\nThe answer is (C)"}]